Understanding Osteoarthritis Today
Moving Beyond Symptom Control
to Disease Modification
Osteoarthritis (OA) management is transitioning from a focus on symptom control to disease modification. Innovative medical approaches are dramatically changing the clinical landscape, setting the stage for improved outcomes in a growing patient population that has jumped by more than one-third in the last decade, with nearly 27 million Americans now diagnosed.
This series brings together an outstanding faculty of OA experts to review the impact of research innovations and treatment developments.
Target Audience
This series is directed to rheumatologists, rheumatology fellows, and other interested health care professionals.
Monograph |
||
 |
Understanding Osteoarthritis Today: Moving Beyond Symptom Control to Disease Modification | |
Estimated Time: 1 hour |
Technical Requirements: Flash Player |
|
Series Objectives
- Identify epidemiologic changes in OA and discuss their impact on clinical practice.
- Assess efficacy and safety data from clinical trials of disease-modifying OA drugs (DMOADs) and gauge their potential impact on clinical practice.
- Discuss new and emerging pain modulators as they apply to the management of patients with OA.
- Discuss the updated pathophysiology of OA.
Activity Director
M. Elaine Husni, MD, MPH
Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Director, Clinical Outcomes Research
Director, Arthritis and Musculoskeletal Treatment Center
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH
